Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan.
COVID-19
SARS-CoV-2
children
post-acute sequelae of SARS-CoV-2 infection
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
27
05
2024
revised:
04
08
2024
accepted:
05
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Post-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic. We enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms. Among 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02-2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13-2.67), sneezing (AOR = 1.68; 95% CI: 1.02-2.76), sputum production (AOR = 1.91; 95% CI: 1.15-3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04-2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13-4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25-0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17-0.78) in children who had received vaccination during the post-COVID-19 phase. This study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase.
Sections du résumé
BACKGROUND
BACKGROUND
Post-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic.
METHODS
METHODS
We enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms.
RESULTS
RESULTS
Among 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02-2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13-2.67), sneezing (AOR = 1.68; 95% CI: 1.02-2.76), sputum production (AOR = 1.91; 95% CI: 1.15-3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04-2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13-4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25-0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17-0.78) in children who had received vaccination during the post-COVID-19 phase.
CONCLUSIONS
CONCLUSIONS
This study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase.
Identifiants
pubmed: 39204035
pii: vaccines12080910
doi: 10.3390/vaccines12080910
pmc: PMC11359259
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : China Medical University Hospital, Taichung, Taiwan
ID : DMR-112-043
Organisme : China Medical University Hospital, Taichung, Taiwan
ID : DMR-112-047
Organisme : China Medical University Hospital, Taichung, Taiwan
ID : DMR-112-052
Organisme : China Medical University Hospital, Taichung, Taiwan
ID : C1110831002-6
Organisme : An-Nan Hospital, China Medical University, Tainan, Taiwan
ID : ANHRF111-03
Références
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
Clin Infect Dis. 2023 Jul 26;77(2):194-202
pubmed: 36905145
J Gen Intern Med. 2022 May;37(7):1748-1753
pubmed: 35266128
Front Microbiol. 2021 Jun 23;12:698169
pubmed: 34248921
BMC Med. 2022 Nov 30;20(1):465
pubmed: 36447237
Arch Dis Child. 2023 Jul;108(7):e12
pubmed: 36863848
Eur J Pediatr. 2022 Dec;181(12):3995-4009
pubmed: 36107254
Int J Mol Sci. 2023 Jan 06;24(2):
pubmed: 36674665
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138
pubmed: 35085223
Vaccine. 2022 Jul 30;40(32):4424-4431
pubmed: 35725782
EClinicalMedicine. 2022 Aug 27;53:101624
pubmed: 36051247
Life (Basel). 2022 Dec 08;12(12):
pubmed: 36556422
Elife. 2023 May 26;12:
pubmed: 37233729
JAMA Pediatr. 2023 Jul 31;:
pubmed: 37523191
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
Int J Mol Sci. 2023 Aug 19;24(16):
pubmed: 37629143
BMJ Med. 2023 Feb 1;2(1):e000229
pubmed: 36910458
J Infect Public Health. 2023 May;16(5):660-672
pubmed: 36931142
BMJ. 2023 Jan 11;380:e072529
pubmed: 36631153
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
JAMA. 2020 Jun 16;323(23):2386-2387
pubmed: 32432681
Eur Rev Med Pharmacol Sci. 2022 Oct;26(20):7695-7704
pubmed: 36314341
JAMA Pediatr. 2022 Oct 1;176(10):1000-1009
pubmed: 35994282
JAMA Netw Open. 2023 Mar 1;6(3):e235763
pubmed: 36995712
BMJ Med. 2023 Feb 1;2(1):e000385
pubmed: 36936268
JAMA. 2023 Jun 13;329(22):1934-1946
pubmed: 37278994
EClinicalMedicine. 2023 May;59:101961
pubmed: 37073325
Vaccines (Basel). 2021 Dec 30;10(1):
pubmed: 35062706
Nat Med. 2022 Jul;28(7):1461-1467
pubmed: 35614233
Arch Dis Child. 2021 Apr 21;106(5):429-439
pubmed: 33262177
PLoS One. 2022 Dec 20;17(12):e0278825
pubmed: 36538532
Front Pediatr. 2021 Oct 29;9:752385
pubmed: 34778143
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
EBioMedicine. 2023 Oct;96:104777
pubmed: 37672869
Lancet Child Adolesc Health. 2022 Sep;6(9):614-623
pubmed: 35752194
Vaccines (Basel). 2023 May 31;11(6):
pubmed: 37376438
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Pediatrics. 2023 Aug 1;152(2):
pubmed: 37476923
JAMA Pediatr. 2023 Apr 1;177(4):384-394
pubmed: 36689319
Brain Behav Immun. 2022 Jul;103:154-162
pubmed: 35447302
Arch Dis Child. 2023 Apr;108(4):289-295
pubmed: 36599625
JAMA Netw Open. 2023 Apr 3;6(4):e235856
pubmed: 37017970
Life (Basel). 2022 Feb 14;12(2):
pubmed: 35207572
Rev Med Virol. 2023 Nov;33(6):e2477
pubmed: 37706263
Clin Exp Pediatr. 2023 Nov;66(11):465-474
pubmed: 37350170
Elife. 2023 Mar 22;12:
pubmed: 36947108
Sci Rep. 2022 Jun 23;12(1):9950
pubmed: 35739136
Lancet Digit Health. 2022 Jul;4(7):e532-e541
pubmed: 35589549
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
Ann Intern Med. 2021 Sep;174(9):1334-1336
pubmed: 34029484
Int J Environ Res Public Health. 2022 Sep 29;19(19):
pubmed: 36231717
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Int J Med Sci. 2021 Jan 1;18(1):29-41
pubmed: 33390771
JAMA. 2021 Jul 15;:
pubmed: 34264266